



Dyanavel® XR (amphetamine) – New formulation approval

- On November 5, 2021, [Tris Pharma announced the FDA approval of Dyanavel XR \(amphetamine\) extended-release tablets](#), for the treatment of attention deficit hyperactivity disorder (ADHD) in patients 6 years and older.
- Dyanavel XR is a Schedule II controlled substance.
- Dyanavel XR was previously available as an extended-release oral suspension.
- Dyanavel XR carries a boxed warning for abuse and dependence.
- Dyanavel XR is contraindicated:
 - In patients known to be hypersensitive to amphetamine, or other components of Dyanavel XR.
 - Patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs.
- Additional warnings and precautions for Dyanavel XR include serious cardiovascular reactions, blood pressure and heart rate increases, psychiatric adverse reactions, long-term suppression of growth, peripheral vasculopathy (including Raynaud's phenomenon), and serotonin syndrome.
- The most common adverse reactions with amphetamine products are dry mouth, anorexia, weight loss, abdominal pain, nausea, insomnia, restlessness, emotional lability, dizziness, and tachycardia.
- The recommended starting dosage of Dyanavel XR is 2.5 mg or 5 mg once daily in the morning. The dosage may be increased in increments of 2.5 mg to 10 mg per day every 4 to 7 days based on clinical response. The maximum recommended dosage is 20 mg once daily.
 - Pharmacological treatment of ADHD may be needed for extended periods. Healthcare providers should periodically re-evaluate the long-term use of Dyanavel XR, and adjust dosage as needed.
 - Dyanavel XR extended-release oral suspension can be substituted with Dyanavel XR extended-release tablets on a milligram per milligram basis.
- Tris Pharma plans to launch Dyanavel XR extended-release tablets in first quarter 2022. Dyanavel XR extended-release tablets will be available as a 5 mg (functionally scored), 10 mg, 15 mg, and 20 mg strength.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.